Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Un ensayo para investigar benralizumab en niños con enfermedades eosinofílicas (CLIPS)

27 de octubre de 2026 actualizado por: AstraZeneca

Fase 3, ensayo abierto para evaluar la seguridad, farmacocinética y eficacia de benralizumab en niños con enfermedades eosinofílicas (CLIPS)

The main purpose of study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of benralizumab.

Descripción general del estudio

Descripción detallada

This study is open-label, multicentre, basket study to evaluate the safety, PK, pharmacodynamic (PD), efficacy, and immunogenicity of repeat dosing of benralizumab subcutaneous (SC) every 4 weeks (Q4W) in male and female children with rare eosinophilic diseases.

Paediatric participants with eosinophilic granulomatosis with polyangiitis (EGPA) will be enrolled in the first cohort.

Paediatric participants with hypereosinophilic syndrome (HES) will be enrolled in the second cohort. Additional cohorts in other eosinophilic diseases may be added in future protocol amendments.

The study consists of 3 periods:

  1. Screening period: 1 to 4 weeks
  2. Open-label treatment period: 52 weeks
  3. Open-label extension period: at least 52 weeks (plus safety follow-up [SFU] weeks after last investigational product [IP] administration)

All eligible participants will receive benralizumab SC Q4W during the 52-week open-label treatment period.

All participants who complete the 52-week open-label treatment period on IP will be offered the opportunity to continue into an extension period. The extension period is intended to allow each participant at least an additional one year of treatment with benralizumab.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

14

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • São Paulo, Brasil, 01232-010
        • Reclutamiento
        • Research Site
    • Ontario
      • Toronto, Ontario, Canadá, M5G1X8
        • Reclutamiento
        • Research Site
    • Colorado
      • Aurora, Colorado, Estados Unidos, 80045
        • Reclutamiento
        • Research Site
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45229
        • Reclutamiento
        • Research Site
      • Highland Hills, Ohio, Estados Unidos, 44106-2624
        • Reclutamiento
        • Research Site
      • Lille, Francia, 59037
        • Reclutamiento
        • Research Site
      • Montpellier, Francia, 34295
        • Suspendido
        • Research Site
      • Ahmedabad, India, 380052
        • Reclutamiento
        • Research Site
      • Petah Tikva, Israel, 49202
        • Reclutamiento
        • Research Site
      • Guadalajara, México, 44620
        • Reclutamiento
        • Research Site
      • Rotterdam, Países Bajos, 3015 GD
        • Reclutamiento
        • Research Site
      • Kielce, Polonia, 25-734
        • Reclutamiento
        • Research Site
      • Warsaw, Polonia, 04-730
        • Aún no reclutando
        • Research Site
      • Altındağ, Turquía (Türkiye), 06230
        • Reclutamiento
        • Research Site
      • Istanbul, Turquía (Türkiye), 34093
        • Reclutamiento
        • Research Site

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

6 años a 17 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

All Cohorts:

  • Male or female participants must be aged 6 to < 18 years of age at the time of signing the assent form and their caregiver signing the informed consent form.
  • Body weight greater than (>=) 15 kilograms (kg).

EGPA Cohort:

  • Therapy with corticosteroids: The prescribed dose of oral corticosteroids (OCS) (greater than [>] 0.1 milligrams per kilogram per day (mg/kg/day), max dose of 50 milligrams per day (mg/day) must be stable (that is, no adjustment of the dose) for at least 4 weeks prior to baseline (Visit 2).
  • Immunosuppressive therapy: If receiving immunosuppressive therapy, the dosage must be stable for at least 4 weeks prior to baseline (Visit 2).

HES Cohort:

  • Documented HES diagnosis, defined as history of persistent eosinophilia >1500 cells/µL without secondary cause on 2 examinations ≥1 month apart and evidence of eosinophil-mediated organ involvement.
  • Symptomatic active HES, or history of a prior flare, or considered eligible based on disease severity per investigator judgement.
  • AEC ≥1000 cells/µL at screening (Visit 1).
  • Documented negative testing for Fip1-like 1 gene fused with the platelet-derived growth factor receptor alpha gene (FIP1L1-PDGFR) fusion tyrosine kinase gene translocation.

Exclusion Criteria:

All Cohorts:

  • Any current malignancy or history of malignancy.
  • History of anaphylaxis to any biologic therapy or vaccine.
  • Known, pre-existing, clinically significant endocrine, autoimmune, metabolic, neurological, renal, gastrointestinal, hepatic, haematological, respiratory, or any other system abnormalities.
  • Previous receipt of benralizumab in an interventional clinical study.

EGPA Cohort:

  • Diagnosed with granulomatosis with polyangiitis (previously known as Wegener'granulomatosis) or microscopic polyangiitis.
  • EGPA relapse: any deterioration in EGPA and/or organ-threatening EGPA that per Investigator judgement renders participants unstable in their EGPA within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2).
  • Life-threatening EGPA: imminently life-threatening EGPA disease within 3 months prior to screening (Visit 1) and through first administration of IP at baseline (Visit 2), as per Investigator judgement.

HES Cohort:

  • Life-threatening HES or HES complications, as judged by the investigator.
  • Hypereosinophilia of unknown significance (HE-US).
  • Diagnosis of systemic mastocytosis.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: EGPA/HES Cohort: Benralizumab

Participants with greater than or equal to (>=) 35 kg weight will receive benralizumab dose-1 and participants with less than (<) 35 kg weight will receive benralizumab dose-2 as SC injection Q4W during the 52-week treatment period. All participants who complete the 52-week treatment period will be offered the opportunity to continue into an extension period.

Benralizumab will be administered as SC injection on Q4W.

Otros nombres:
  • FASENRA

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of Participants with Adverse Events (AEs)
Periodo de tiempo: From screening (Week -4 to -1) until Week 52

The safety and tolerability of benralizumab will be evaluated.

From screening (Week -4 to -1) until Week 52
Serum Concentrations of Benralizumab
Periodo de tiempo: Weeks 0, 12, 24, 25, 36, and 52

The PK of benralizumab will be evaluated.

Weeks 0, 12, 24, 25, 36, and 52

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
EGPA Cohort: Percentage of Participants with Remission at Week 24
Periodo de tiempo: At Week 24

Remission defined as Paediatric Vasculitis Activity Score (PVAS) = 0 and oral corticosteroid (OCS) intake less than or equal to (<=) 0.1 mg/kg/day.

At Week 24
Number of Participants with Positive Antidrug Antibody (ADA)
Periodo de tiempo: Weeks 0, 12, 24, 36, 48, and 52

The immunogenicity of benralizumab will be evaluated.

Weeks 0, 12, 24, 36, 48, and 52
Change From Baseline in Peripheral Blood Eosinophil Count
Periodo de tiempo: From Baseline to Weeks 0, 12, 24, 36, 52

The PD effect of benralizumab on peripheral blood eosinophil count will be evaluated.

From Baseline to Weeks 0, 12, 24, 36, 52
EGPA Cohort: Time to First EGPA Relapse
Periodo de tiempo: Up to 52 weeks

The efficacy of benralizumab on time to first relapse will be assessed. EGPA relapse will be defined as worsening or persistence of active disease since the last visit characterized by: a) Active vasculitis (PVAS > 0); OR b) Worsening of asthma symptoms (based on Asthma Control Questionnaire - Interviewer Administered [ACQ-IA]); OR c) Active nasal and/or sinus disease with worsening in at least one sino-nasal symptom question warranting any of the following: 1) Increase OCS; OR 2) Increase/addition of immunosuppressive medication; OR 3) Hospitalisation related to EGPA worsening.

Up to 52 weeks
HES Cohort: Time to first HES worsening/flare
Periodo de tiempo: Up to 52 weeks

The effect of benralizumab on HES worsening/flares will be evaluated.

Up to 52 weeks
HES Cohort: Percentage of participants who experience a HES worsening/flare
Periodo de tiempo: Up to 52 weeks

The effect of benralizumab on HES worsening/flares will be evaluated.

Up to 52 weeks
HES Cohort: Number of HES worsening/flares (annualised rate/year)
Periodo de tiempo: Up to 52 weeks

The effect of benralizumab on HES worsening/flares will be evaluated. The annualised HES worsening/flare rate will be calculated as follows:

The total number of flares *365.25 / total duration of follow-up in the treatment period (days).

Up to 52 weeks
HES Cohort: Percentage of Participants requiring an increase in corticosteroid dose
Periodo de tiempo: Up to 52 weeks

The effect of benralizumab on corticosteroid use will be evaluated.

Up to 52 weeks
HES Cohort: Time to first haematologic relapse
Periodo de tiempo: Up to 52 weeks

The time to first haematologic relapse will be defined as the time from first dose of IP to the first post baseline visit with Absolute eosinophil count [AEC] ≥ 1000 cells/uL.

Up to 52 weeks
HES Cohort: Percentage of Participants with haematologic relapse
Periodo de tiempo: Up to 52 weeks

The effect of benralizumab on haematologic measures of disease activity will be evaluated.

Up to 52 weeks
HES Cohort: Percentage of Participants who have AEC < 500 cells/μL for 24 weeks
Periodo de tiempo: Up to 52 weeks

The effect of benralizumab on haematologic measures of disease activity will be evaluated.

Up to 52 weeks
HES Cohort: Patient Global Impression of Change (PGI-C) Score
Periodo de tiempo: Weeks 12, 24, 36 and 48

The effect of benralizumab on participant/caregiver reported measures of disease severity and health status will be assessed. The PGI-C instrument captures the participant's overall evaluation of response to treatment, and rated on a 7-point PGI-C scale ranging from 1 ('much better') to 7 ('much worse').

Weeks 12, 24, 36 and 48

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

17 de abril de 2025

Finalización primaria (Estimado)

20 de febrero de 2028

Finalización del estudio (Estimado)

14 de mayo de 2029

Fechas de registro del estudio

Enviado por primera vez

17 de julio de 2024

Primero enviado que cumplió con los criterios de control de calidad

17 de julio de 2024

Publicado por primera vez (Actual)

22 de julio de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

28 de octubre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

27 de octubre de 2026

Última verificación

1 de octubre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • D3255C00004
  • 2023-508533-14-00 (Otro identificador: EU CT)
  • EMEA-001214-PIP09-21-M02(EGPA) (Otro identificador: Paediatric Investigational Plan Number)
  • EMEA-001214-PIP04-19-M02 (HES) (Otro identificador: Paediatric Investigational Plan Number)
  • 2023 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via there quest portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

Marco de tiempo para compartir IPD

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Criterios de acceso compartido de IPD

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir